Status:
COMPLETED
Effects of Synvisc on Cartilage in Knee Osteoarthritis (OA)
Lead Sponsor:
Endeavor Health
Collaborating Sponsors:
Genzyme, a Sanofi Company
Northwestern University
Conditions:
Osteoarthritis
Eligibility:
All Genders
40-80 years
Phase:
PHASE1
Brief Summary
Hylan G-F 20 (Synvisc) is an FDA-approved hyaluronate derivative used to treat knee osteoarthritis (OA). Animal studies have shown that Synvisc can have favorable effects on cartilage when injected in...
Detailed Description
Hylan G-F 20 (Synvisc) is an FDA-approved hyaluronate derivative which is administered by injection into osteoarthritic joints for the treatment of osteoarthritis. Preclinical investigations have demo...
Eligibility Criteria
Inclusion
- Males and females 40 to 80 years of age who meet the ACR Criteria for osteoarthritis of the knee.
- Radiographic evidence of OA, Kellgren and Lawrence grade I to III on prior X-rays (taken within 6 months of the screening visit) or at screening. Only the tibio-femoral joint will be evaluated (patello-femoral disease will not be considered).
- Mild to moderate levels of knee pain as determined by a VAS pain score of 3-6/10 that has been stable for at least 1 month prior to screening visit.
- Stable management regimen for knee OA pain for at least 1 month prior to screening visit. Subjects can be managed by physical measures alone, simple analgesics, NSAIDs, nutriceuticals or other agents with no significant change in treatment regimen during the 1 month prior to screening visit.
- Ability to comply with the requirements of the study
- Able to maintain stable exercise/activity program during course of the study
- 6\. Signed and dated consent form 7. Women of child-bearing potential should agree to the use of an appropriate method of contraception and have a confirmed negative pregnancy test at screening.
Exclusion
- Radiographic evidence of Kellgren and Lawrence grade IV OA
- Knee pain \<3 or \>6 out of 10 on VAS pain scale.
- Change in management regimen for knee OA during the preceding month.
- Subjects with any metal implant such as cardiac pacemakers, spinal cord stimulators or bionic ear devices.
- Subjects who are unable to receive gadolinium contrast agent injection because of contraindications.
- Unable to undergo an MRI exam because of contraindication, e.g. claustrophobia.
- Inflammatory arthritis, e.g. rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus.
- History of other diseases that may involve the study joint including inflammatory joint disease, crystalline disease, endocrinopathies, metabolic disease, knee infection of the chosen knee, neuropathic disorders, avascular necrosis, Paget's disease or tumors
- Recent trauma to study joint.
- Known loose bodies in the study joint.
- Patients taking oral steroids.
- Patients with active malignancy.
- Patients who are either high-performance athletes or, in the opinion of the investigator, are highly sedentary and not likely to ambulate at least 20-30 minutes/day.
- In the opinion of the investigator, the subject has an unstable medical condition.
- Participating in another study or has participated in a study evaluating investigational drugs, devices or biologics within three months of enrollment in this study.
- Study subject has ever previously received hyaluronan therapy.
- Arthroscopic or open surgery to the study joint within the previous twelve months.
- Anticipated need for knee surgery to the study joint.
- History of joint replacement, intra-articular fracture, osteotomy, arthroplasty or meniscectomy of the study knee.
- Intra-articular injection of corticosteroid to study joint within the past six months.
- Morbid obesity defined as BMI of greater than 40.
- Study subject has known sensitivity to any component of Hylan G-F 20 including bird feathers, eggs or poultry.
- Subject has an active systemic infection.
- Subject on coumadin or other anticoagulant.
- Musculoskeletal pain that may preclude the subject from remaining motionless for the MRI exam.
- Women who are pregnant or lactating.
- Subjects with "clinically significant" malalignment.
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2009
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00949494
Start Date
September 1 2006
End Date
February 1 2009
Last Update
September 10 2019
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Northwestern University
Chicago, Illinois, United States, 60611
2
Northshore University Hospital
Evanston, Illinois, United States, 60201